Therapy Directory

Ipilimumab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Ipilimumab as a study intervention. Browse Ipilimumab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 7:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

640

Shown on this page

Current sort

Live official records

Open in full search

Conditions: B-Cell Non-Hodgkin Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma, T-Cell Non-Hodgkin Lymphoma
Interventions: Ipilimumab, Lenalidomide; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer, Hepatocellular
Interventions: nivolumab, ipilimumab, TACE; Drug · Procedure
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 5
States / cities: Coronado, California • Washington D.C., District of Columbia • Louisville, Kentucky + 1 more

Conditions: Acute Myeloid Leukemia and Myelodysplastic Syndrome
Interventions: Nivolumab, Ipilimumab; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Melanoma, Ocular, Melanoma, Cutaneous, Metastatic Melanoma, Melanoma, Mucosal, Liver Metastases
Interventions: Ipilimumab, Nivolumab, Stereotactic Body Radiation Therapy; Drug · Procedure
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Breast Cancer
Interventions: Cryoablation, Ipilimumab, Nivolumab; Procedure · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage III Lung Cancer
Interventions: Biospecimen Collection, Carboplatin, Computed Tomography, Fludeoxyglucose F-18, Nab-paclitaxel, Pembrolizumab, Pemetrexed, Positron Emission Tomography, Radiation Therapy, [18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan, Ipilimumab, Nivolumab, Cemiplimab, Atezolizumab; Procedure · Drug · Other + 2 more
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Metastatic Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions: Aldesleukin, Autologous CD8+ Melanoma Specific T Cells, Cyclophosphamide, Ipilimumab, Laboratory Biomarker Analysis; Biological · Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Refractory Cutaneous Melanoma
Interventions: Ipilimumab, Nivolumab, Cabozantinib; Drug
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Renal Cell Carcinoma
Interventions: Entinostat, Nivolumab, Ipilimumab; Drug
Lead sponsor: Roberto Pili; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Indianapolis, Indiana

Conditions: Pan Tumor
Interventions: Nivolumab, Ipilimumab; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 10
States / cities: Santa Monica, California • Denver, Colorado • Minneapolis, Minnesota + 7 more

Conditions: Pancreatic Cancer
Interventions: Cyclophosphamide, Nivolumab, Ipilimumab, GVAX Pancreas Vaccine, CRS-207; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Melanoma
Interventions: Relatlimab, Ipilimumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: Tucson, Arizona • Los Angeles, California • Santa Monica, California + 4 more

About this Ipilimumab clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Ipilimumab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Ipilimumab.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Ipilimumab clinical trials

Filter and sort this therapy

Live official records

Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies

A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer

Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant

Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)

A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma

A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer

A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment

About this Ipilimumab clinical trials directory page